Phibro Animal Health (PAHC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual Meeting scheduled for November 5, 2024, at the company’s Teaneck, NJ offices.
Proxy materials are primarily available online, with options for paper or email copies upon request.
Only shareholders of record as of September 13, 2024, are eligible to vote at the meeting.
Voting matters and shareholder proposals
Election of two Class II Directors, Mary Lou Malanoski and Carol A. Wrenn, to serve until the 2027 Annual Meeting.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending June 30, 2025.
Board recommends voting FOR both proposals.
Board of directors and corporate governance
Board of Directors is responsible for nominating director candidates and making recommendations on voting matters.
Judith A. Weinstein serves as Senior Vice President, General Counsel, and Corporate Secretary.
Latest events from Phibro Animal Health
- Record sales and profit growth in FY26, with continued expansion expected in FY27.PAHC
Q4 2026 - Acquisition-driven growth and innovation are strengthening margins and expanding global reach.PAHC
Stifel Jaws & Paws Conference 2025 - Strong growth, innovation, and sustainability initiatives position the business for continued expansion.PAHC
Stifel 2026 Jaws & Paws Conference - Broad-based growth, new sustainability platform, and regulatory adaptation drive future outlook.PAHC
Bank of America Global Healthcare Conference 2026 - Q3 sales up 10% to $383.5M, with strong Animal Health growth and upgraded FY2026 guidance.PAHC
Q3 2026 - Strong growth, successful integration, and strategic continuity define the outlook.PAHC
BofA Securities Animal Health Summit - Net sales up 21% and EBITDA up 41%, prompting a raised outlook amid strong Animal Health growth.PAHC
Q2 2026 - Q1 sales up 13% and Zoetis deal drive strong growth and profitability rebound.PAHC
Q1 2025 - Growth strategy leverages Zoetis deal, Phibro Forward, and robust demand for sustained expansion.PAHC
Morgan Stanley 22nd Annual Global Healthcare Conference - Animal Health growth and Zoetis acquisition drive optimism despite lower net income.PAHC
Q4 2024